# St0 Cx)SUMMARY

1. Date the summary was prepared:

March 6, 2013

Submitter's name: Address:

Phone:

Guangzhou Wondfo Biotech Co., Ltd. South China University of Technology Guangzhou, P.R. China 510641 012-86-20-32296069

Name of contact person:

Joe Shia   
LSI International Inc.   
504 East Diamond Ave.,   
Suite F Gaithersburg, MD 20877 Telephone: 240-505-7880   
Fax: 301-916-6213

3. Name of the device Common or usual name: Trade or proprietary name:

Multi-Drug Urine Test Cup Multi-Drug Urine Test Panel Wondfo Multi-Drug Urine Test Cup Wondfo Multi-Drug Urine Test Panel

Classification: All are Class Il medical devices with the following various product codes with Code of Federal Regulation references:   

<table><tr><td rowspan=1 colspan=1>Product Code</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>Regulation Section</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>DKZAmphetamine</td><td rowspan=1 colspan=1>II</td><td rowspan=1 colspan=1>21 CFR § 862.3100, AmphetamineTest System</td><td rowspan=1 colspan=1>Toxicology(91)</td></tr><tr><td rowspan=1 colspan=1>LDJCannabinoids</td><td rowspan=1 colspan=1>II</td><td rowspan=1 colspan=1>21 CFR § 862.3870, CannabinoidsTest System</td><td rowspan=1 colspan=1>Toxicology(91)</td></tr><tr><td rowspan=1 colspan=1>DIOCocaine</td><td rowspan=1 colspan=1>II</td><td rowspan=1 colspan=1>21 CFR § 862.3250, Cocaine andCocaine Metabolites Test System</td><td rowspan=1 colspan=1>Toxicology(91)</td></tr><tr><td rowspan=1 colspan=1>LAFMethamphetamine</td><td rowspan=1 colspan=1>II</td><td rowspan=1 colspan=1>21 CFR § 862.3610,Methamphetamine Test System</td><td rowspan=1 colspan=1>Toxicology(91)</td></tr><tr><td rowspan=1 colspan=1>DJGMorphine 2000</td><td rowspan=1 colspan=1>II</td><td rowspan=1 colspan=1>21.CFR § 862.3650, MorphineTest System</td><td rowspan=1 colspan=1>Toxicology(91)</td></tr><tr><td rowspan=1 colspan=1>LAFMethylenedioxymethamphetamine</td><td rowspan=1 colspan=1>II</td><td rowspan=1 colspan=1>21 CFR § 862.3610,Methamphetamine Test System</td><td rowspan=1 colspan=1>Toxicology(91)</td></tr><tr><td rowspan=1 colspan=1>DJGMorphine</td><td rowspan=1 colspan=1>II</td><td rowspan=1 colspan=1>21 CFR § 862.3650, MorphineTest System</td><td rowspan=1 colspan=1>Toxicology(91)</td></tr><tr><td rowspan=1 colspan=1>BuprenorphineDJG</td><td rowspan=1 colspan=1>II</td><td rowspan=1 colspan=1>21 CFR § 862.3650, Opiate testsystem</td><td rowspan=1 colspan=1>Toxicology(91)</td></tr><tr><td rowspan=1 colspan=1>JXMOxazepam</td><td rowspan=1 colspan=1>II</td><td rowspan=1 colspan=1>21 CFR § 862.3170,Benzodiazepine Test System</td><td rowspan=1 colspan=1>Toxicology(91)</td></tr><tr><td rowspan=1 colspan=1>DJGOxycodone</td><td rowspan=1 colspan=1>II</td><td rowspan=1 colspan=1>21 CFR § 862.3650, Opiate TestSystem</td><td rowspan=1 colspan=1>Toxicology(91)</td></tr><tr><td rowspan=1 colspan=1>LCMPhencyclidine</td><td rowspan=1 colspan=1>.unclassified</td><td rowspan=1 colspan=1>Enzyme ImmunoassayPhencyclidine</td><td rowspan=1 colspan=1>Toxicology(91)</td></tr><tr><td rowspan=1 colspan=1>DISSecobarbital</td><td rowspan=1 colspan=1>II</td><td rowspan=1 colspan=1>21 CFR § 862.3150, BarbiturateTest System</td><td rowspan=1 colspan=1>Toxicology(91)</td></tr></table>

4. Description of the device:

Wondfo Multi-Drug Urine Test Cup and Wondfo Multi-Drug Urine Test Panel are competitive binding, lateral flow immunochromatographic assays for qualitative and simultaneous detection of Amphetamine, Secobarbital," Oxazepam, Cocaine, Cannabinoids, Methamphetamine, Methylenedioxymethamphetamine, Morphine, Morphine 2000, Phencyclidine, Oxycodone and Buprenorphine in human urine samples. Wondfo Multi-Drug devices detect each of analytes on different strips.   
A positive urine sample will not generate a colored-line for the specific drug tested in the designated region. A negative urine specimen or a urine sample containing Amphetamine, Secobarbital, Oxazepam. Cocaine, Cannabinoids, Methamphetamine, Methylenedioxymethamphetamine, Morphine, Morphine 2000, Phencyclidine, Oxycodone and Buprenorphine at the concentration below the designated cutof levels will generate a colored line in the designated test region for the drug.To serve as a test control, a color line will always appear at the control region.

5. Intended use of the device:

Wondfo Multi-Drug Urine Test Cup and Wondfo Multi-Drug Urine Test Panel are competitive binding, lateral flow immunochromatographic assays for qualitative and simultaneous detection of Amphetamine, Secobarbital," Oxazepam, Cocaine, Cannabinoids,, Methamphetamine, Methylenedioxymethamphetamine, Morphine, Morphine 2000, Phencyclidine, Oxycodone and Buprenorphine in human urine at the cutoff concentrations of:

<table><tr><td rowspan=1 colspan=1>.</td><td rowspan=1 colspan=1>Drug(Identifier)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Cut-off level</td></tr><tr><td rowspan=1 colspan=1>Amphetamine(AMP)</td><td></td><td></td><td rowspan=1 colspan=1>1000 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Secobarbital (BAR)</td><td></td><td></td><td rowspan=1 colspan=1>300 ng/mL</td></tr><tr><td rowspan=1 colspan=3>Oxazepam (BZO)</td><td rowspan=1 colspan=1>300 ng/mL</td></tr><tr><td rowspan=1 colspan=3>Cocaine (COC)</td><td rowspan=1 colspan=1>300 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Cannabinoids (THC)</td><td></td><td></td><td rowspan=1 colspan=1>50 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Methamphetamine (MET)</td><td></td><td></td><td rowspan=1 colspan=1>1000 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Methylenedioxymet</td><td></td><td></td><td rowspan=1 colspan=1>500 ng/mL</td></tr><tr><td rowspan=1 colspan=3>Morphine (MOP)</td><td rowspan=1 colspan=1>300 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Morphine 2000 (OPT)</td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1>2000 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Phencyclidine (PCP)</td><td></td><td></td><td rowspan=1 colspan=1>25 ng/mL</td></tr><tr><td rowspan=1 colspan=3>Oxycodone (OXY)</td><td rowspan=1 colspan=1>100 ng/mL</td></tr><tr><td rowspan=1 colspan=3>Buprenorphine (BUP)</td><td rowspan=1 colspan=1>10 ng/mL</td></tr></table>

Couration heWono Mulir UriTupndWon ultirUrTe consist of any combination of the above listed drug analytes.

The test provides only preliminary test results. A more speciflc alternative chemical method must be u n rder  obta a con nalycl esult.C/S  /S s he pefered cony method.

The test wil yield preliminary positive results when prescription drugs Buprenorphine, Oxazepam, Oxycodone and Secobarbital are ingested, even at or above therapeutic doses. Clinical consideration and professional judgment should be exercised with any drug of abuse test result, particularly when the preliminary result is positive.

# Comparison to the predicate device

Wono Multi-Drug Urine Test Cup and Wondo Multi-Drug Urine Test Panel are a modifed" product format derived from the previously FDA-cleared Wondfo single DOA Tests. A summary comparison of features of Won MultDrg UriTest Cup nd Won MultDrug UrieTest Paneland reica evicesi provided in the following Table

<table><tr><td>Item</td><td>New Devices</td><td>Predicate devices (K112071)</td></tr><tr><td>Indication(sfor use</td><td>For the qualitative determination of Amphetamine (AMP), Secobarbital (BAR), Oxazepam (BZO), Cocaine (COC), Cannabinoids (THC), Methamphetamine (MET), Methylenedioxymethamphetamine (MDMA),</td><td>For the qualitative determination of Cocaine (COC), or Methamphetamine (MET), in human urine. The configurations of the Predicate devices are</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Morphine (MOP), Morphine2000 (OPI),Phencyclidine (PCP), Oxycodone(OXY)and/orBuprenorphine in human urine.The configurations of the New Devices areavailable in any combination of the above tests.</td><td colspan="1" rowspan="1">only available in single drug test.</td></tr><tr><td colspan="1" rowspan="1">Methodology</td><td colspan="1" rowspan="1">Competitive     binding,      lateral     flowimmunochromatographic assays based on theprinciple of antigen antibody immunochemistry.</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Type Of Test</td><td colspan="1" rowspan="1">Immunoassay principles that rely on antigen-antibody interactions to indicate positive ornegative result</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Results</td><td colspan="1" rowspan="1">Qualitative</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Specimen Type</td><td colspan="1" rowspan="1">Human urine</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Cut Off Values</td><td colspan="1" rowspan="1">Amphetamine (AMP): 1,000 ng/mlSecobarbital(BAR): 300 ng/mlOxazepam (BZO):300 ng/mlCocaine(COC): 300 ng/mlCannabinoids (THC):50 ng/mlMethamphetamine (MET): 1,000 ng/mlMethylenedioxymethamphetamine (MDMA): 500ng/mlMorphine (MOP): 300 ng/mlMorphine 2000 (OPI): 2000 ng/mlPhencyclidine (PCP): 25 ng/mlOxycodone(OXY) : 100 ng/mlBuprenorphine (BUP): 10 ng/ml</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Configurations</td><td colspan="1" rowspan="1">Cup, dip card</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">OTC Use &amp; Prescription Use</td><td colspan="1" rowspan="1">Same</td></tr></table>

Wondfo Multi-Drug Urine Test Cup is a multi-drug test that offers any combination from 2 to 12 drugs of abuse tests while the predicate devices are single-drug test. And the Wondfo Multi-Drug Urine Test Panel is the same as the test dip card format of the predicate devices except that the Wondfo Multi-Drug Urine Test Panel is a multi-drug test that offers any combination from 2 to 12 drugs of abuse tests while the predicate devices are single-drug test.

April 9, 2013

GUANGZHOU WONDFO BIOTECH CO., LTD. C/O JOE SHIA   
REGULATORY CONSULTANT   
504E DIAMOND AVE:, SUITE F   
GAITHERSBURG MD 20877

Re: K130665 Trade/Device Name: Wondfo Multi-Drug Urine Test Cup, Wondfo Multi-Drug Urine Test Panel Regulation Number: 21 CFR 862.3650 Regulation Name: Opiate test system Regulatory Class: II Product Code: DJG, DKZ, LDJ, DIO, LAF, JXM, LCM, DIS Dated: March 06, 2013 Received: March 12, 2013

Dear Mr. Shia:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of . devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class II (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be foud in the Code of Federal Regulations, Tite , art 800 to 8 In adition, FA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000- 1050.

If you desire specific advice for your device on our labeling regulations (21 CFR Parts 801 and 809), please contact the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Intemet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

# Caro

jon-s for

Courtney H. Lias, Ph.D.   
Director   
Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostics   
and Radiological Health   
Center for Devices and Radiological Health

# Indications for Use

510(k) Number (if known): k130665

# Device Name: Wondfo Multi-Drug Urine Test Cup Wondfo Multi-Drug Urine Test Panel

Indications for Use:

Wondfo Multi-Drug Urine Test Cup is competitive binding, lateral flow immunochromatographic assay for qualitative and simultaneous detection of Amphetamine, Secobarbital, Oxazepam, Cocaine, Cannabinoids, Methamphetamine, Methylenedioxymethamphetamine, Morphine, Morphine 2000, Phencyclidine, Oxycodone and Buprenorphine in human urine at the cutoff concentrations of:

(PLEASE DO NOT WRITE BELOW THIS LINE; CONTINUE ON ANOTHER PAGE IF NEEDED)   

<table><tr><td rowspan=1 colspan=1>Drug(Identifier)</td><td rowspan=1 colspan=1>Cut-off level</td></tr><tr><td rowspan=1 colspan=1>Amphetamine(AMP)</td><td rowspan=1 colspan=1>1000 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Secobarbital (BAR)</td><td rowspan=1 colspan=1>300 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Oxazepam (BZO)</td><td rowspan=1 colspan=1>300 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Cocaine (COC)</td><td rowspan=1 colspan=1>300 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Cannabinoids (THC)</td><td rowspan=1 colspan=1>50 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Methamphetamine (MET)</td><td rowspan=1 colspan=1>1000 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Methylenedioxymethamphetamine (MDMA)</td><td rowspan=1 colspan=1>500 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Morphine (MOP)</td><td rowspan=1 colspan=1>300 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Morphine 200 (OPI)</td><td rowspan=1 colspan=1>2000 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Phencyclidine (PCP)</td><td rowspan=1 colspan=1>25 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Oxycodone (OXY)</td><td rowspan=1 colspan=1>100 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Buprenorphine (BUP)</td><td rowspan=1 colspan=1>10 ng/mL</td></tr></table>

Concurrence of CDRH, Office of In Vitro Diagnostics and Radiological Health (OIR)

510(k) Number (if known): k130665 .

# Device Name: Wondfo Multi-Drug Urine Test Cup Wondfo Multi-Drug Urine Test Panel

Indications for Use:

Configuration of the Wondfo Multi-Drug Urine Test Cup can consist of any combination of the above listed drug analytes.

The test provides only preliminary test results. A more specific alternative chemical method must be used in order to obtain a confirmed analytical result. GC/MS or LC/MS is the preferred confirmatory method.

The test will yield preliminary positive results when prescription drugs Buprenorphine, Oxazepam, Oxycodone and Secobarbital are ingested, even at or above therapeutic doses.

Clinical consideration and professional judgment should be exercised with any drug of abuse test result, particularly when the preliminary result is positive.

# Concurrence of CDRH, Office of In Vitro Diagnostics and Radiological Health (OIR)

# Indications for Use

510(k) Number (if known): k130665

# Device Name: Wondfo Multi-Drug Urine Test Cup Wondfo Multi-Drug Urine Test Panel

Indications for Use:

Wondfo Multi-Drug Urine Test Panel is competitive binding, lateral flow immunochromatographic assay for qualitative and simultaneous detection of Amphetamine, Secobarbital, Oxazepam, Cocaine, Cannabinoids, Methamphetamine, Methylenedioxymethamphetamine, Morphine, Morphine 2000, Phencyclidine, Oxycodone and Buprenorphine in human urine at the cutoff concentrations of:

(PLEASE DO NOT WRITE BELOW THIS LINE; CONTINUE ON ANOTHER PAGE IF NEEDED)   

<table><tr><td rowspan=1 colspan=1>Drug(Identifier)</td><td rowspan=1 colspan=1>Cut-off level</td></tr><tr><td rowspan=1 colspan=1>Amphetamine(AMP)</td><td rowspan=1 colspan=1>1000 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Secobarbital (BAR)</td><td rowspan=1 colspan=1>300 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Oxazepam (BZO)</td><td rowspan=1 colspan=1>300 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Cocaine (COC)</td><td rowspan=1 colspan=1>300 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Cannabinoids (THC)</td><td rowspan=1 colspan=1>50 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Methamphetamine (MET)</td><td rowspan=1 colspan=1>1000 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Methylenedioxymethamphetamine (MDMA)</td><td rowspan=1 colspan=1>500 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Morphine (MOP)</td><td rowspan=1 colspan=1>300 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Morphine 2000 (OPI)</td><td rowspan=1 colspan=1>2000 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Phencyclidine (PCP)</td><td rowspan=1 colspan=1>25 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Oxycodone (OXY)</td><td rowspan=1 colspan=1>100 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Buprenorphine (BUP)</td><td rowspan=1 colspan=1>10 ng/mL</td></tr></table>

Concurrence of CDRH, Office of In Vitro Diagnostics and Radiological Health (OIR)

Division Sign-Off Office of In Vitro Diagnostics and Radiological Health

# Indications for Use

510(k) Number (if known): k130665

# Device Name: Wondfo Multi-Drug Urine Test Cup Wondfo Multi-Drug Urine Test Panel

Indications for Use:

Configuration of the Wondfo Multi-Drug Urine Test Panel can consist of any combination of the above listed drug analytes.

The test provides only preliminary test results. A more specific alternative chemical method must be used in order to obtain a confirmed analytical result. GC/MS or LC/MS is the preferred confirmatory method.

The test will yield preliminary positive results when prescription drugs Buprenorphine, Oxazepam, Oxycodone and Secobarbital are ingested, even at or above therapeutic doses. Clinical consideration and professional judgment should be exercised with any drug of abuse test result, particularly when the preliminary result is positive.

Prescription Use _X And/Or Over the Counter Use _X (21 CFR Part 801 Subpart D) (21 CFR Part 801 Subpart C)

Concurrence of CDRH, Office of In Vitro Diagnostics and Radiological Health (OIR)

Division Sign-Off Office of In Vitro Diagnostics and Radiological Health